Digestery
Longevity supplements › NMN and Aging › Studies

Randomized trial · measured other health measures

A 26-week NR trial in people with Werner syndrome: less artery stiffness, smaller ulcers

Shoji and colleagues · Aging cell · 2025

Original title: Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

No serious side effects. Artery stiffness score (CAVI) improved, skin ulcer area decreased, and blood creatinine fell. Heel pad thinning showed a declining trend.

The study at a glance

Type of study
Randomized trial
Who or what was studied
People with Werner syndrome, a rare disease of early aging
What was tested
NR 1,000 mg once a day for 26 weeks vs placebo for 26 weeks (crossover)
What it measured
Several kinds of outcomes
Daily amount
1000 mg a day
How long
26 weeks
Who has a stake
Company stake
ChromaDex supplied NR and placebo and signed contracts with the university; authors declare no competing interests.
Journal
Aging cell, 2025
Source
PubMed record 40459998. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • •The abstract does not say how many people took part.
  • •Lasted 26 weeks.
  • •Measured several kinds of outcomes.
  • –Company stake: ChromaDex supplied NR and placebo and signed contracts with the university; authors declare no competing interests.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    0

    Not done yet. This is the step that would answer the question.

  2. Trials in people: other measures

    9

    3 benefit, 2 mixed, 4 no difference

    ↑ This study is the ringed dot

  3. Trials in people: lab tests or safety

    7

    4 benefit, 1 mixed, 2 no difference

  4. Population studies

    0

    None among the papers we read.

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    6

    5 benefit, 1 mixed

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does NMN slow aging?”

Not shown in people so far.

Confidence: very low. Based on 29 on-topic papers.

Read the full answer

Of the other 8 papers on the same step: 2 benefit, 2 mixed, 4 no difference. This one found benefit.

Other papers on the same step

See all 29 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads differed. The reviewer checked the abstract and kept the first read. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.